Literature DB >> 10906419

K6/ODC transgenic mice as a sensitive model for carcinogen identification.

Y Chen1, L C Megosh, S K Gilmour, J A Sawicki, T G O'Brien.   

Abstract

Ornithine decarboxylase (ODC), an important enzyme in the polyamine biosynthetic pathway, is aberrantly regulated in many epithelial tumors of rodents and humans. In murine skin, it has been shown that ODC overexpression provides a sufficient condition for tumor promotion. Therefore, we hypothesized that K6/ODC transgenic mice in which ODC overexpression was targeted to hair follicle keratinocytes might provide a sensitive model for identifying genotoxic carcinogens. Ten known carcinogens or noncarcinogens have been tested in the model so far and results are highly concordant with 2-year rodent bioassays (100% concordant). More importantly, each of two chemicals tested that is recognized as a human carcinogen was identified as a carcinogen in K6/ODC transgenic mice. In addition, 7, 12-dimethylbenz(a)anthracene (DMBA) dose response studies indicated that even at a very low dose, 2 nmol, a high percentage of mice (50%) had already developed tumors 8 weeks after treatment. We conclude that the K6/ODC transgenic mouse model is very sensitive to topical application of genotoxic carcinogens and could therefore be a useful mouse model for carcinogen identification and chemical risk assessment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906419     DOI: 10.1016/s0378-4274(00)00196-x

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  16 in total

1.  Elevated ornithine decarboxylase activity promotes skin tumorigenesis by stimulating the recruitment of bulge stem cells but not via toxic polyamine catabolic metabolites.

Authors:  Candace S Hayes; Karen DeFeo-Mattox; Patrick M Woster; Susan K Gilmour
Journal:  Amino Acids       Date:  2013-07-25       Impact factor: 3.520

2.  Association between the ornithine decarboxylase G316A polymorphism and breast cancer survival.

Authors:  Linping Xu; Jianping Long; Peng Wang; Kangdong Liu; Ling Mai; Yongjun Guo
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

Review 3.  Cancer in experimental animals exposed to arsenic and arsenic compounds.

Authors:  Erik J Tokar; Lamia Benbrahim-Tallaa; Jerrold M Ward; Ruth Lunn; Reeder L Sams; Michael P Waalkes
Journal:  Crit Rev Toxicol       Date:  2010-11       Impact factor: 5.635

4.  Activation and up-regulation of translation initiation factor 4B contribute to arsenic-induced transformation.

Authors:  Yong Zhang; Qing Wang; Xiaoling Guo; Robert Miller; Yinglu Guo; Hsin-Sheng Yang
Journal:  Mol Carcinog       Date:  2011-01-25       Impact factor: 4.784

Review 5.  Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer.

Authors:  Rachelle R Olsen; Bruce R Zetter
Journal:  Mol Cancer Res       Date:  2011-08-17       Impact factor: 5.852

6.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

7.  Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Authors:  Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 8.  The mechanistic basis of arsenicosis: pathogenesis of skin cancer.

Authors:  Katherine M Hunt; Ritesh K Srivastava; Craig A Elmets; Mohammad Athar
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

Review 9.  Targeting polyamine metabolism for cancer therapy and prevention.

Authors:  Tracy R Murray-Stewart; Patrick M Woster; Robert A Casero
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

10.  Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs.

Authors:  W Bunjobpol; I Dulloo; K Igarashi; N Concin; K Matsuo; K Sabapathy
Journal:  Cell Death Differ       Date:  2014-04-11       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.